Actuate Therapeutics holds 2026 Annual Meeting; elects Fletcher and Keyes as directors, ratifies Crowe LLP as auditor

ACTUATE THERAPEUTICS, INC.

Elected Aaron G.L. Fletcher, Ph.D. and Jason Keyes as Class II directors for three-year terms through 2029.
Fletcher received 14,877,247 for, 1,883,025 withheld; Keyes received 16,727,875 for, 32,397 withheld.
Ratified Crowe LLP as independent auditor for FY 2026 with 18,571,817 for, 50,023 against, 9,741 abstain.
Broker non-votes: 1,871,309 on director elections; none on auditor ratification.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ACTUATE THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-21 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

ratified the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ACTUATE THERAPEUTICS, INC. shareholders approved Election of two Class II director nominees at the 2026-05-21 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

elected each of the two Class II director nominees listed below to the Company's Board of Directors, each to serve for a three-year term until the 2029 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified

View on SEC.gov

556 shareholder votes filed in the last 30 days. Browse all shareholder votes →

ACTUATE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001683168-26-004268

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.